<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350619</url>
  </required_header>
  <id_info>
    <org_study_id>GHELP</org_study_id>
    <nct_id>NCT04350619</nct_id>
  </id_info>
  <brief_title>NGS Assessment of Congenitally Deafned Children and Neonatal Deafness Screnning</brief_title>
  <acronym>GHELP</acronym>
  <official_title>Promote Personalized Medicine Based on Diagnostic Genomic Tools in Order to Innovate in the Early Detection of Child Deafness in the SUDOE Space (European International Project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Pública y Laboral de Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociacion Instituto Biodonostia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DREAMgenics S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital CUF Porto, S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar de Lisboa Central</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the diagnostic value of NGS screnning in prelingually deafned children using a new
      designed chip, and to evaluate its interest in a the neonatal screening program for
      ddetecting congenitally deafned children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the diagnostic value of a new panel of gene in NGS study
      in children presenting :

        1. A congenitally deafness : it is a retrospective study in children aged 0 to 17 yrs with
           hearing thresholds over 40 dB in the best ear using adapted audiometric assessment,

        2. A suspicion of deafness in babies aged 0 to 6 months having an abnormal response after
           otoacoustic emissions and automated ABR assessment.

      The main outcomes studied will be the finding of a pathogenic mutation (or several
      mutations).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of mutation</measure>
    <time_frame>1 day</time_frame>
    <description>It will realized the extraction blood sample in the same day and clinical information will be collected also.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phenotyping the mutation</measure>
    <time_frame>1 day</time_frame>
    <description>Clinical information for each patient will be define for the following variables: age and gender, medical antecedents, audiometric data, other syndromic syntomps, ear radiologic data and type of treatment for treating the hearing loss.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Congenital Deafness</condition>
  <condition>Suspicion of Congenital Deafness</condition>
  <arm_group>
    <arm_group_label>Genetic study in retrospective and prospective groups</arm_group_label>
    <description>Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic screening. No therapeutic intervention</intervention_name>
    <description>Genetic screening using NGS technique. No therapeutic intervention</description>
    <arm_group_label>Genetic study in retrospective and prospective groups</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for genetic study
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There are 2 groups: retrospective and prospective which their characteristiques are
        described in the previous eligibility criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Retropective study

        Inclusion criteria:

          -  Age of onset of deafness between 0 and 17 years

          -  With a hearing loss of one or two senses with, on the ear most affected, a hearing
             loss more than 40 dB in mean audiometric loss in behavioural audiometry

          -  Availability of detailed information in Appendix 1: History, history and course of
             disease, associated symptoms, otoscopy data, radiology, treatments and hearing aids
             implemented.

          -  Availability of DNA samples stored in an existing collection.

          -  Consent to participate in the study (non-opposition) by the legal representative

        Exclusion Criteria:

          -  Exclusion criteria:

               -  Child with a known cause of observed deafness (meningitis, post-surgery or drug
                  iatrogenic, trauma, infections, tumor)

               -  Family not willing to participate in the study

        Prospective study

        Inclusion criteria:

          -  Age of the child 0 to 6 months including corrected age having had on at least one of
             the two ears a lack of acoustic otoemissions and a lack of response in automated PEA,
             and a threshold of PEA at least on one ear at more than 40 dB.

          -  Availability of detailed information in Appendix 2: Personal history, family history
             of deafness, associated symptoms, tympanometry, otoscopy data, neonatal deafness test
             data.

          -  Collection of the consent of the legal representative

        Exclusion criteria:

        · Family not willing to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mondain, ENT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Jesús M Manrique Rodriguez, ENT</last_name>
    <phone>948255400</phone>
    <phone_ext>4651</phone_ext>
    <email>mmanrique@unav.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Mondain, Prof</last_name>
      <email>m-mondain@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deafness</keyword>
  <keyword>child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

